Source link : https://www.newshealth.biz/health-news/battle-continues-over-compounded-glp-1s/
The US Food and Drug Administration (FDA) has notified compounding pharmacies that the agency — at least temporarily — won’t take action against them for creating copies of the dual glucagon-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) drug tirzepatide (Eli Lilly and Company). Meanwhile, Novo Nordisk, which makes semaglutide, has asked the FDA to add the […]
Author : News Health
Publish date : 2024-10-28 13:11:12
Copyright for syndicated content belongs to the linked Source.
